我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

加味二陈汤对非酒精性脂肪性肝病大鼠血清瘦素的影响(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2020年05期
页码:
1-5,27
栏目:
实验研究
出版日期:
2020-12-30

文章信息/Info

Title:
Effect of Modified Erchen Decoction on Serum Leptinin Non-alcoholic Fatty Liver Disease Rats
文章编号:
1000-2723(2020)05-0001-05
作者:
杜冰1王佳宁2杨艳3洪力1闫龙腾1罗德霞1姚政1 4
1. 云南中医药大学,云南 昆明 650500;2. 榆林市教育示范性综合实践基地,陕西 榆林 719000;3. 云南省临沧卫生学校,云南 临沧 677000;4. 云南省高校中医证候微观辨证重点实验室,云南 昆明 650500
Author(s):
DU Bing1 WANG Jianing2 YANG Yan3 HONG Li1 LUO Dexia1 YAN Longteng1 YAO Zheng1 4
1. Yunnan University of Chinese Medicine, Kunming 650500, China;2. Yulin Education Demonstration Comprehensive Practice Base, Yulin 719000, China;3. Yunnan Lincang Health College, Lincang 677000, China;4. Key Laboratory of Microcosmic Syndrome Differentiation, Education Department of Yunnan,Kunming 650500, China
关键词:
加味二陈汤非酒精性脂肪性肝病瘦素
Keywords:
modified Erchen Decoction non-alcoholic fatty liver leptin
分类号:
R285.5
DOI:
10.19288/j.cnki.issn.1000-2723.2020.05.001
文献标识码:
A
摘要:
目的〓观察加味二陈汤对非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)大鼠血脂、肝脂与血清瘦素水平的影响。方法 SD大鼠(80只)随机分为4组,每组20只,正常组予普通饲料喂养,模型组、辛伐他汀组(1.8 mg/kg)、加味二陈汤组(4.5 g/kg)予高脂饲料喂养。于第9周开始灌胃给药,持续4周。分别于10、12周末观察各组大鼠体质量、肝重、肝组织HE染色、肝功能(AST)、血脂(血TG、HDL-C、LDL-C)、肝脂(肝TG)、血清瘦素水平。结果 10、12周末病理切片结果显示,高脂饮食大鼠肝脏出现典型的脂肪肝病变。生化指标及ELISA结果显示,模型组肝功能、血脂、肝脂及血清瘦素水平明显升高。加味二陈汤组较模型组,肝脂、血脂水平下降,脂质沉积和脂肪肝变性程度有所改善,血清瘦素水平明显下调(P<0.05)。结论 加味二陈汤可下调血清瘦素水平,下调血脂、肝脂水平,表明加味二陈汤可能通过化痰祛瘀法治疗非酒精性脂肪性肝病,而降低瘦素水平可能是其作用机制之一。
Abstract:
Objective To observe the effects of modified Erchen Decocion on the levels of blood lipid, liver fat and serum leptin in rats with non-alcoholic fatty liver disease. Methods 80 SD rats were randomly divided into normal control group, model group, simvastatin group(1.8 mg/kg) and modified Erchen Decoction group(4.5 g/kg), with 20 rats in each group. The normal group were fed with ordinary diet, the other groups were fed with high-fat diet. Gavage was started at the 9th week and lasted for 4 weeks. The weight, liver weight, HE staining, liver function (AST), blood lipids (blood TG, HDL-C, LDL-C), liver lipids(liver TG), serum leptin level were detected. Results At the end of 10 and 12 weeks, pathological results showed that the liver of high-fat diet rats with a typical hepatic steatosis. Biochemical and ELISA results showed, the liver function, blood lipids, liver lipids and serum leptin level in the model group were significantly increased. Compared with model group, the degree of lipid deposition and liver steatosis in modified Erchen Decoction group had obviously improved, and the level of serum leptin was significantly reduced(P<0.05). Conclusion Modified Erchen Decoction could ruduce serum leptin level, lower blood lipids and liver lipids levels. This indicated that modified Erchen Decoction could treat non-alcoholic fatty liver and the mechanism may be related to leptin reducing.

参考文献/References

[1] ZHOU J, ZHOU F, WANG W, et al. Epidemiological Features of NAFLD From 1999 to 2018 in China[J] . Hepatology,2020,71(5):1851-1864.
[2] MASARONE M, FEDERICO A, ABENAVOLI L, et al. Non alcoholic fatty liver: epidemiology and natural history[J]. Rev Recent Clin Trials,2014,9(3):126-133.
[3] LONARDO A,NASCIMBENI F,MANTOVANI A,et al. Hypertension,diabetes,atherosclerosis and NASH:Cause or consequence?[J] . J Hepatol,2018,68(2):335-352.
[4] ESTES C,ANSTEE Q M,ARIAS-LOSTE M T, et al. Modeling NAFLD disease burden in China, France, Germany,Italy,Japan,Spain,United Kingdom,and United States for the period 2016-2030[J]. J Hepatol,2018,69(4):896-904.
[5] POLYZOS S A, KOUNTOURAS J, MANTZOROS C S. Leptin in nonalcoholic fatty liver disease:a narrative review[J]. Metabolism, 2015,64(1):60-78.
[6] Moon H S, Dalamaga M, Kim S Y, et al. Leptin’s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals[J]. Endocr Rev,2013,34(3):377-412.
[7] MANTZOROS C S, MAGKOS F, BRINKOETTER M, et al. Leptin in human physiology and pathophysiology[J]. Am J Physiol Endocrinol Metab,2011,301(4):E567-E584.
[8] 程玉佩,张明香. 从痰瘀论治非酒精性脂肪肝研究进展[J]. 辽宁中医药大学学报,2018,20(11):157-160.
[9] 潘丰满,桂壮. 二陈汤加味治疗高脂血症性非酒精性脂肪性肝病42例[J]. 长江大学学报(自然科学版)医学卷,2010,7(4):13-14.
[10] 徐水根. 中西医结合治疗非酒精性脂肪性肝病痰瘀互结证48例临床观察[J]. 新中医,2015,47(12):63-65.
[11] 陈柏安. 二陈汤加味治疗高脂血症90例[J]. 浙江中医杂志,2008,43(11):678.
[12] 姚政,王佳宁,陈滟,等. 加味二陈汤对非酒精性脂肪肝大鼠UCP2影响的动态观察[J]. 时珍国医国药,2017,28(11):2589-2591.
[13] 詹潇潇,梁惠卿,唐金模. 基于“痰湿”理论谈非酒精性脂肪性肝病的中医治疗[J]. 中西医结合肝病杂志,2020,30(1):90-92.
[14] 张顺贞,季章龙,姚政,等. 从痰瘀理论探讨非酒精性脂肪肝的治疗[J]. 云南中医中药杂志,2015,36(6):21-23.
[15] 王健,张倩,郭卉. 祛瘀化痰法治疗非酒精性脂肪肝病的研究进展[J]. 内蒙古中医药,2016,35(1):164-165.
[16] LI S, XU Y, GUO W, et al. The impacts of herbal medicines and natural products on regulating the hepatic lipid metabolism[J]. Front Pharmacol,2020,11:351.
[17] 李伟娜,马素平. 马素平教授运用消法治疗非酒精性脂肪性肝病经验[J]. 中医研究,2018,31(1):48-50.
[18] 李青融,王子妤. 三七总皂苷药理作用的研究进展[J]. 湖南中医杂志,2017,33(9):216-218.
[19] 毛柳珺,蔡小玲,廖曾珍. 三七总皂苷对神经系统疾病药理作用机制的研究[J]. 当代医药论丛,2017,15(15):48-49.
[20] PAN W W,MYERS M G J R. Leptin and the maintenance of elevated body weight[J]. Nat Rev Neurosci,2018,19(2):95-105.
[21] DARDENO T A, CHOU S H, MOON H S, et al. Leptin in human physiology and therapeutics[J]. Front Neuroendocrinol, 2010,31(3):377-393.
[22] ROTUNDO L,PERSAUD A,FEURDEAN M,et al. The Association of leptin with severity of non-alcoholic fatty liver disease: A population-based study[J]. Clin Mol Hepatol,2018,24(4):392-401.

备注/Memo

备注/Memo:
收稿日期: 2020 - 08- 30 基金项目: 国家自然科学基金项目(81860812);云南省应用基础研究项目(2013FZ093);云南省应用基础研究-中医联合 专项[2017FF116(-021)] ?div>第一作者简介: 杜冰(1995-),女,在读硕士研究生,研究方向:中西医结合防治肝胆疾病基础研究。?/div>
?通信作者: 姚政,E-mail:yaozhmail@126.com
更新日期/Last Update: 1900-01-01